SCHEMBL3391887

SCHEMBL3391887

Cc1cc(C(=O)O)c2ccccc2c1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NR4A1 P22736 1/20 0.57
NR4A2 P43354 1/20 0.57
NR4A3 Q92570 1/20 0.57
CYP1A2 P05177 2/20 0.53
CYP2A6 P11509 1/20 0.53
KDM4E B2RXH2 3/20 0.52
MEN1 O00255 2/20 0.52
KMT2A Q03164 2/20 0.52
ALDH1A1 P00352 2/20 0.52
HSD17B10 Q99714 2/20 0.52
GLA P06280 1/20 0.52
HPGD P15428 1/20 0.52
CYP2C19 P33261 1/20 0.52
CDC25B P30305 3/20 0.51
RXFP1 Q9HBX9 1/20 0.51
GPR35 Q9HC97 2/20 0.49
POLB P06746 1/20 0.49
PTPN1 P18031 1/20 0.49
WDR5 P61964 1/20 0.48
TTR P02766 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31256575 1.00 NR4A1 (0.57) NR4A1NR4A2NR4A3CYP1A2CYP2A6
SCHEMBL14852738 0.85 KDM4E (0.47) NR4A1NR4A2NR4A3CYP1A2KDM4E
SCHEMBL6362640 0.85 CYP1A2 (0.53) NR4A1NR4A2NR4A3CYP1A2CYP2A6
SCHEMBL12316910 0.83 KDM4E (0.53) NR4A1NR4A2NR4A3CYP1A2CYP2A6
SCHEMBL17919668 0.80 PLK1 (0.64) CYP1A2CYP2A6KDM4EKMT2AALDH1A1
SCHEMBL28245095 0.80 CYP1A2 (0.48) NR4A1NR4A2NR4A3CYP1A2CYP2A6
SCHEMBL29254661 0.80 CYP1A2 (0.48) NR4A1NR4A2NR4A3CYP1A2CYP2A6
SCHEMBL31533158 0.80 NR4A1 (0.61) NR4A1NR4A2NR4A3CYP1A2KDM4E
SCHEMBL344157 0.79 PTPN1 (0.66) NR4A1NR4A2NR4A3CYP1A2KDM4E
SCHEMBL31522164 0.79 PTPN1 (0.66) NR4A1NR4A2NR4A3CYP1A2KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0244167-B1 IMPROVED PROCESS FOR PREPARING POLY (ARYL ETHERS) AND POLY (ARYL ETHER KETONES) AMOCO CORPORATION (US) 1990-04-04 EP claimed
US-4748227-A Process for preparing poly(aryl ether)ketones using a sodium carbonate/organic acid salt catalyst AMOCO CORPORATION (US) 1988-05-31 US claimed
EP-0244167-A1 Improved process for preparing poly (aryl ethers) and poly (aryl ether ketones) AMOCO CORPORATION (US) 1987-11-04 EP claimed
US-20230330099-A1 SUBSTITUTED INDOLE MCL-1 INHIBITORS VANDERBILT UNIVERSITY 2023-10-19 US disclosed
US-20220185785-A1 INHIBITORS OF CD40-CD154 BINDING TONIX Pharmaceuticals Holding Corp (US) 2022-06-16 US disclosed
EP-3230339-B1 EPOXY RESIN COMPOSITION, PREPREG, FIBER-REINFORCED PLASTIC MATERIAL, AND MANUFACTURING METHOD FOR FIBER-REINFORCED PLASTIC MATERIAL TORAY INDUSTRIES (JP) 2022-03-23 EP disclosed
EP-3952853-A1 INHIBITORS OF CD40-CD154 BINDING Tonix Pharmaceuticals Holding Corp. (US) 2022-02-16 EP disclosed
WO-2020210831-A1 INHIBITORS OF CD40-CD154 BINDING TONIX Pharmaceuticals Holding Corp (US) 2020-10-15 WO disclosed
CN-107001594-B Composition epoxy resin, prepreg, the manufacturing method of fiber reinforced plastic materials and fiber reinforced plastic materials 东丽株式会社 2019-07-23 CN disclosed
US-10005721-B2 Dimethylbenzoic acid compounds ELI LILLY AND COMPANY (US) 2018-06-26 US disclosed
US-20170362376-A1 EPOXY RESIN COMPOSITION, PREPREG, FIBER-REINFORCED PLASTIC MATERIAL, AND MANUFACTURING METHOD FOR FIBER-REINFORCED PLASTIC MATERIAL TORAY INDUSTRIES, INC. (JP) 2017-12-21 US disclosed
US-4061661-A Δ9(11) -5α-20-KETO STEROIDS AND PROCESS FOR THEIR PRODUCTION SCHERING AKTIENGESELLSCHAFT (DT) 1977-12-06 US disclosed
US-4032540-A BENZOPYRAN DERIVATIVES SCHERING AKTIENGESELLSCHAFT (DT) 1977-06-28 US disclosed
US-4021458-A Process for the preparation of 3-hemisulfate-17α-hydroxy steroids SCHERING AKTIENGESELLSCHAFT (DT) 1977-05-03 US disclosed
US-4016269-A 17α-HYDROXY-1,3,5(10),15-ESTRATETRAENES AND PROCESS FOR THEIR PRODUCTION SCHERING AKTIENGESELLSCHAFT (DT) 1977-04-05 US disclosed
US-4012510-A Novel methylene steroids SCHERING AKTIENGESELLSCHAFT (DT) 1977-03-15 US disclosed
US-4011314-A FOR TREATING ESTROGEN DEFICIENCY SCHERING AKTIENGESELLSCHAFT (DT) 1977-03-08 US disclosed
US-4001298-A RADIOPAQUE AGENTS SCHERING AKTIENGESELLSCHAFT (DT) 1977-01-04 US disclosed
US-3962280-A PROCESS FOR PREPARING BENZOPYRAN DERIVATIVES SCHERING AKTIENGESELLSCHAFT (DT) 1976-06-08 US disclosed
US-3939204-A IODO SUBST. DICARBOXYLIC ACID ANTILIDES SCHERING AKTIENGESELLSCHAFT (DT) 1976-02-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230330099-A1 SUBSTITUTED INDOLE MCL-1 INHIBITORS MCL1, BCL2L1, BCL9 NR4A1 3610/4885NR4A2 2684/4885NR4A3 3103/4885
US-20220185785-A1 INHIBITORS OF CD40-CD154 BINDING CD40LG, CD40, CD4 NR4A1 235/4885NR4A2 472/4885NR4A3 191/4885
US-10005721-B2 Dimethylbenzoic acid compounds PTGER4, EDNRB, EPB41 NR4A1 54/4885NR4A2 102/4885NR4A3 71/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.